Ekso Bionics(TM) Completes Training at Switzerland's Largest Rehabilitation Center
15 July 2014 - 9:00PM
Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton
company, announced today that SPC Nottwil has finished training
their team of physiotherapists with their Ekso GT™ robotic
exoskeleton for neurorehabilitation and started to book patients to
learn how to walk again. SPC Nottwil is the largest of
Switzerland's four special clinics for para and tetraplegics; they
consistently treat over 70% of all people with spinal paralysis in
Switzerland and are fully occupied all year round. They have joined
an esteemed group of European centers with an Ekso™ robotic
exoskeleton including the top rated Insitut Guttman in Spain and
The Clinic for Spinal Cord Injuries in Hornbaek, Denmark, now part
of Glostrup Hospital. Robotic exoskeletons have been gaining
adoption in the neurorehabilitation community as a strong and
growing body of evidence shows they are able to engage the
principles of neuroplasticity for improved patient outcomes.
"It's a huge accomplishment for us to be in these three top
rated rehabilitation hospitals in Europe," said Ekso Bionics chief
executive officer Nate Harding. "The fact that such leading centers
purchased our devices and are making our device available to their
patients is exciting – that is what I'd call winning the 'Triple
Crown' of European rehab."
Recent studies in Europe have shown a range of potential
benefits using the Ekso GT robotic exoskeleton in
neurorehabilitation. In a study at BG Hospital Bergmannstrost
Halle, measuring quality of life, patients reported their pain was
reduced from walking in an Ekso Bionics robotic exoskeleton. The
Company believes pain reduction is a particularly meaningful
benefit when one considers a possible correlating reduction of
medication and side effects. Bergmannstrost also reported a
reduction in spasticity and an overall improvement in quality of
life. All 13 subjects stated that the ability to stand and walk
over ground again had a definite positive effect in mental
wellbeing. As the study described, "To be able to approach someone
at eye level and literally be able 'to look someone in the eye'
again was often described as incredible." These results outline
some of the reasons that neurorehabilitation centers around the
world are integrating Ekso Bionics technology into their
practice.
Ekso Bionics designs, develops, and commercializes exoskeletons,
or wearable robots, which have a variety of applications in the
medical, military, industrial, and consumer markets. Exoskeletons
are ready-to-wear, battery-powered robots that are strapped over
the user's clothing, enabling individuals to achieve mobility,
strength, and endurance not otherwise possible. Ekso Bionics' lead
product, Ekso, is a wearable bionic suit that enables individuals
with any amount of lower extremity weakness to stand up and walk
over ground. It is the only robotic exoskeleton to offer variable
assist which provides varying amounts of power to each side and
makes it an optimal rehabilitation device for those with
hemiplegia. With a CE 2A classification in Europe and a class 1 FDA
approval in the United States, Ekso is forging a new frontier in
rehabilitation for people living with the consequences of stroke,
spinal cord injury and other neurological conditions affecting
gait.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of
robotic exoskeletons, or wearable robots, to augment human
strength, endurance and mobility. The company's first commercially
available product called Ekso has helped thousands of people living
with paralysis take millions of steps not otherwise possible. By
designing and creating some of the most forward-thinking and
innovative solutions for people looking to augment human
capabilities, Ekso Bionics is helping people rethink current
physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on
the OTC QB under the symbol EKSO. To learn more about Ekso Bionics
please visit us at www.eksobionics.com
Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube:http://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without
limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives
relating to the design, development and commercialization of human
exoskeletons, (ii) a projection of income (including income/loss),
earnings (including earnings/loss) per share, capital expenditures,
dividends, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not meant
to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing, the significant length of time and resources
associated with the development of our products and related
insufficient cash flows and resulting illiquidity, the Company's
inability to expand the Company's business, significant government
regulation of medical devices and the healthcare industry, lack of
product diversification, volatility in the price of the Company's
raw materials, existing or increased competition, results of
arbitration and litigation, stock volatility and illiquidity, and
the Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including, the
Company's Current Report on Form 8-K filed on March 31, 2014 and
the Company's latest Form 10-Q filed on May 13, 2014. The Company
does not undertake to update these forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024